Pharma Pulse: FDA Blocks Compounded GLP-1 Ingredients, RSV Vaccination Benefits Seniors, and Pharmacies Struggle With Pricing Program

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering new FDA restrictions on GLP-1 compounding, fresh data on RSV immunization in older adults, and challenges pharmacy owners face in a federal drug pricing program.

• The FDA has updated its “green list” of bulk drug substances, blocking certain active ingredients from being used in the compounding of GLP-1 therapies. The decision aims to curb the rise of unauthorized compounded semaglutide products, which regulators warn pose potential safety and quality risks. With GLP-1 demand continuing to outpace supply, the ruling reinforces the FDA’s stance on protecting patients by steering prescribers and pharmacies toward approved, regulated products.
• In other news, new research shows that RSV immunization in adults aged 60 and older not only reduces the risk of respiratory illness but also provides cardiorespiratory benefits, such as lowering the risk of exacerbations in patients with chronic heart and lung disease. Experts say the findings strengthen the case for widespread adoption of RSV vaccination in older populations, particularly as the virus contributes to significant seasonal morbidity.
• Lastly, community pharmacy owners report they are unable to participate in the Medicaid Drug Price Negotiation Program, citing eligibility and structural barriers. Many say the system favors larger players, leaving independents at a disadvantage despite their role in providing front-line patient care. Industry advocates are calling for reforms to ensure that small and mid-sized pharmacies can access the program and remain financially sustainable in a tightening reimbursement environment.

From FDA enforcement to vaccination benefits and pricing inequities, these stories highlight the regulatory and market pressures shaping patient care today.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.